By
Intas Pharma files DRHP with SEBI; ChrysCapital eyes 13-14x part-exit

Ahmedabad-based Intas Pharmaceuticals Ltd has filed draft red-herring prospectus (DRHP) with the market regulator for an issue which will see ChrysCapital part-exit with over 13-14x returns, said ...

TO READ THE FULL STORY


Leave Your Comment(s)